Observational studyShock (Augusta, Ga.)2026
Early Immune Phenotype-Guided Immunomodulatory Strategies and Intensive Care Outcomes in Septic Shock: A Single-Center Retrospective Cohort Study.
Observational study in Shock (Augusta, Ga.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeptic shock is characterized by profound immune dysregulation, with marked heterogeneity in host inflammatory and immunosuppressive responses. This biological variability may contribute to the inconsistent effects observed in prior immunomodulatory interventions. Whether early immune phenotype-guided immunomodulation is associated with differential patterns of shock resolution and organ recovery remains incompletely understood.
methodsWe conducted a single-center retrospective observational cohort study of adult patients with septic shock. Immune phenotyping using routinely available biomarkers was performed as part of standard clinical care within the first hour after shock onset. Using a prespecified 24-hour landmark design, patients were retrospectively classified according to early treatment with hemoadsorption, IgM-enriched intravenous immunoglobulin (IVIG), or standard care. The primary outcome was vasopressor-free days through day 28. Secondary outcomes included 28-day mortality, lactate kinetics, ventilator-free days, and changes in Sequential Organ Failure Assessment score. Propensity score-weighted analyses were applied to adjust for baseline differences in patient characteristics associated with routine clinical practice.
resultsAmong 1,216 patients included in the landmark cohort, vasopressor-free days through day 28 were highest in patients treated with hemoadsorption, followed by those receiving IgM-enriched IVIG, and lowest in the standard care group. Hemoadsorption was associated with faster lactate clearance, whereas IgM-enriched IVIG was associated with greater improvement in Sequential Organ Failure Assessment score by day 5. Twenty-eight-day mortality differed across groups, with the lowest mortality observed in the hemoadsorption group.
conclusionsAmong patients with septic shock who survived beyond the first 24 hours, early immune phenotype-guided immunomodulatory strategies applied during routine care were associated with distinct patterns of hemodynamic stabilization and organ recovery. These findings should be interpreted as associative and hypothesis-generating and support further investigation in prospective phenotype-stratified studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.